Safety
DILI, eosinophilia, liver injury, Toxicity, DRESS
ADVERSE EVENT, DRUG REACTION, EOSINOPHILIA, ADVERSE EVENT, PUSTULAR PSORIASIS
By Week 1, 11 patients (68.8%) in the spesolimab group and eight patients (61.5%) in the placebo group had reported at least one AE (Table Adverse events occurring in Asian patients in the Effisayil™ 1 studyAbbreviations: AE, adverse event; DILI, drug‐induced liver injury; DRESS, drug reaction with eosinophilia and systemic symptoms; RCTC, Rheumatology Common Toxicity Criteria.Shown are the number of AEs occurring between the start of treatment and the end of the residual effect period. For patients who received optional spesolimab on or after Day 8, the residual effect period was 16 weeks after the last dose of study medication. AEs occurring during the residual effect period were considered “treatment‐emergent” and coded using the Medical Dictionary for Drug Regulatory Activities version 23.1.AEs reported in ≥10% of patients in any group. AE severity was graded according to the RCTC version 2.0 safety analysis set. Pustular psoriasis was excluded as an AE from this safety analysis.